First Product in Market
One Touch® Verio® glucose test
OneTouch Verio is the first blood glucose product launched by LifeScan that uses Universal Biosensors’ innovative opposing electrode technology. LifeScan, a Johnson and Johnson company, first introduced OneTouch Verio to the market in January 2010 and is now available in much of Europe and Australia and further launches are anticipated throughout 2011. OneTouch Verio has been positively received by the market based on key competitive advantages that stem directly from the novel electrochemical approach. The OneTouch Verio represents world-class technology that utilises Universal Biosensors’ highly automated, state of the art manufacturing system.
Key advantages of UBI's technology in Verio TM
- Enables instant, (within seconds) readings of blood glucose levels
- Requires no calibration and uses a tiny finger prick blood sample (less than 0.5µL)
- The result is unaffected by the presence of unrelated sugars such as maltose and galactose which interfere with the results in a number of other blood glucose systems
Glucose Monitoring
Point-of-care tests for blood glucose first appeared in the market in the late 1980s. These simple test devices allowed patients to take control of their insulin medication and led to dramatic advances in life expectancy and quality of life for diabetics. Today it is estimated 16-18 billion disposable sensor strips using electrochemical cells are used by diabetics each year. This remains the largest market in the point-of-care segment and has been valued at more than US$9.8 billion globally and continues to grow.
In Australia, the OneTouch Verio can be found at http://www.onetouch.com.au/
Our success in blood glucose testing validates the Universal Biosensors business model — to partner with leading companies to develop world class products.